Literature DB >> 11287578

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.

M Nees1, J M Geoghegan, T Hyman, S Frank, L Miller, C D Woodworth.   

Abstract

Infection with high-risk human papillomaviruses (HPV) is a major risk factor for development of cervical cancer. Expression of the HPV E6 and E7 oncoproteins increases in differentiating keratinocytes, resulting in inactivation of the p53 and retinoblastoma proteins, two important transcriptional regulators. We used cDNA microarrays to examine global alterations in gene expression in differentiating cervical keratinocytes after infection with retroviruses encoding HPV type 16 (HPV-16) E6 and E7. Expression of 80 cellular genes (approximately 4% of the genes on the array) was altered reproducibly by E6 and/or E7. Cluster analysis classified these genes into three functional groups: (i) interferon (IFN)-responsive genes, (ii) genes stimulated by NF-kappaB, and (iii) genes regulated in cell cycle progression and DNA synthesis. HPV-16 E6 or a dominant negative p53 protein downregulated multiple IFN-responsive genes. E6 decreased expression of IFN-alpha and -beta, downregulated nuclear STAT-1 protein, and decreased binding of STAT-1 to the IFN-stimulated response element. E7 alone was less effective; however, coexpression of E6 and E7 downregulated IFN-responsive genes more efficiently than E6. The HPV-16 E6 protein also stimulated expression of multiple genes known to be inducible by NF-kappaB and AP-1. E6 enhanced expression of functional components of the NF-kappaB signal pathway, including p50, NIK, and TRAF-interacting protein, and increased binding to NF-kappaB and AP-1 DNA consensus binding sites. Secretion of interleukin-8, RANTES, macrophage inflammatory protein 1alpha, and 10-kappaDa IFN-gamma-inducible protein were increased in differentiating keratinocytes by E6. Thus, high-level expression of the HPV-16 E6 protein in differentiating keratinocytes directly alters expression of genes that influence host resistance to infection and immune function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287578      PMCID: PMC114174          DOI: 10.1128/JVI.75.9.4283-4296.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

Review 1.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  Nerve growth factor protects human keratinocytes from ultraviolet-B-induced apoptosis.

Authors:  A Marconi; C Vaschieri; S Zanoli; A Giannetti; C Pincelli
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

3.  Nerve growth factor activation of nuclear factor kappaB through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells.

Authors:  J J Gentry; P Casaccia-Bonnefil; B D Carter
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

4.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

Authors:  T R Golub; D K Slonim; P Tamayo; C Huard; M Gaasenbeek; J P Mesirov; H Coller; M L Loh; J R Downing; M A Caligiuri; C D Bloomfield; E S Lander
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

5.  Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431.

Authors:  B Metzner; C Hofmann; C Heinemann; U Zimpfer; I Schraufstätter; E Schöpf; J Norgauer
Journal:  Oncol Rep       Date:  1999 Nov-Dec       Impact factor: 3.906

6.  The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.

Authors:  S Li; S Labrecque; M C Gauzzi; A R Cuddihy; A H Wong; S Pellegrini; G J Matlashewski; A E Koromilas
Journal:  Oncogene       Date:  1999-10-14       Impact factor: 9.867

7.  Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31.

Authors:  Y E Chang; L A Laimins
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.

Authors:  D Patel; S M Huang; L A Baglia; D J McCance
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

9.  Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis.

Authors:  I V Budunova; P Perez; V R Vaden; V S Spiegelman; T J Slaga; J L Jorcano
Journal:  Oncogene       Date:  1999-12-09       Impact factor: 9.867

10.  Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta.

Authors:  H Harada; M Matsumoto; M Sato; Y Kashiwazaki; T Kimura; M Kitagawa; T Yokochi; R S Tan; T Takasugi; Y Kadokawa; C Schindler; R D Schreiber; S Noguchi; T Taniguchi
Journal:  Genes Cells       Date:  1996-11       Impact factor: 1.891

View more
  129 in total

Review 1.  [HPV-associated squamous cell carcinogenesis].

Authors:  G Assmann; K Sotlar
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

2.  IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis.

Authors:  Astrid C Baege; Gary L Disbrow; Richard Schlegel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

4.  Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization.

Authors:  Erik R Vandermark; Krysta A Deluca; Courtney R Gardner; Daniel F Marker; Cynthia N Schreiner; David A Strickland; Katelynn M Wilton; Sumona Mondal; Craig D Woodworth
Journal:  Virology       Date:  2012-01-28       Impact factor: 3.616

5.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

6.  Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.

Authors:  Allison J Berger; Astrid Baege; Tracy Guillemette; James Deeds; Ron Meyer; Gary Disbrow; Richard Schlegel; Robert Schlegel
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31.

Authors:  Yijan E Chang; Loren Pena; Ganes C Sen; Jung K Park; Laimonis A Laimins
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 8.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Highly tissue substructure-specific effects of human papilloma virus in mucosa of HIV-infected patients revealed by laser-dissection microscopy-assisted gene expression profiling.

Authors:  Nicole Baumgarth; Richard Szubin; Greg M Dolganov; Mitchell R Watnik; Deborah Greenspan; Maria Da Costa; Joel M Palefsky; Richard Jordan; Mario Roederer; John S Greenspan
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Effect of TLR4 on the growth of SiHa human cervical cancer cells via the MyD88-TRAF6-TAK1 and NF-κB-cyclin D1-STAT3 signaling pathways.

Authors:  Li Ma; Li Feng; Xiaoping Ding; Yongwang Li
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.